FUSION ANTIBODIES PLC

FORM OF PROXY

ANNUAL GENERAL MEETING

I/We

.....................................................................................................................................(FULL NAME(S) IN BLOCK CAPITALS)

of ................................................................................................................................................

(ADDRESS IN BLOCK CAPITALS)

being (a) member(s) of the above named Company, appoint the Chairman of the meeting OR the following person*:

Name of proxy

Number of shares in relation to

which the proxy is authorised to act

(*please refer to Explanatory Note 2)

as my/our proxy to exercise all or any of my/our rights to attend, speak and vote in respect of my/our voting entitlement on my/our behalf at the annual general meeting of the Company to be held at The Malone Hotel, 60 Eglantine Avenue, Malone Road, Belfast, BT9 6DY on 24 September 2021 at 11.00 a.m. and at any adjournment of the meeting.

*Please note that in light of the Covid-19 pandemic situation and the consequent risk of local restrictions on travel and meetings, Shareholders are urged to appoint the Chairman of the meeting as his or her proxy.

Please tick here if this proxy appointment is one of multiple appointments being made.

(For the appointment of more than one proxy, please refer to Explanatory Note 3.)

I/We would like my/our proxy to vote on the resolutions to be proposed at the meeting as indicated on this form. Unless otherwise

instructed, the proxy can vote as he or she chooses or can decide not to vote at all in relation to any business of the meeting.

VOTE

ORDINARY RESOLUTIONS

FOR

AGAINST

WITHHELD

1.

To receive the Company's annual accounts and the strategic, directors' and

auditor's reports for the year ended 31 March 2021

2.

To reappoint Richard Jones who retires having been appointed as a director after

the last AGM, as a director

3.

To reappoint Alan Mawson who retires by rotation, as a director

4.

To reappoint Colin Walsh who retires by rotation, as a director

5.

To reappoint Tim Watts, who retires by rotation, as a director

6.

To reappoint PricewaterhouseCoopers LLP as auditors

7.

To authorise the Audit Committee to determine the remuneration of the auditors

8.

To authorise the directors to allot relevant securities

SPECIAL RESOLUTIONS

9.

To empower the directors to allot relevant securities on a non-pre-emptive basis

10.

To authorise the Company to make market purchases of ordinary shares

Signature

Date

2021

Notes to the Form of Proxy

These notes should be read in conjunction with the notes to the Notice of Meeting relating to attending the Annual General Meeting in person and your attention is particularly drawn to notes 2 and 3 below.

  1. As a member of the Company you are entitled to appoint a proxy or proxies to exercise all or any of your rights to attend, speak and vote at a general meeting of the Company. You can only appoint a proxy using the procedures set out in these notes. If the proxy is being appointed in relation to part of your holding only, please enter in the box next to the proxy's name the number of shares in relation to which they are authorised to act as your proxy. If this box is left blank they will be authorised in respect of your full voting entitlement. This form of proxy confers authority to demand or join in demanding a poll.
  2. Appointment of a proxy does not preclude you from attending the meeting and voting in person. If you have appointed a proxy and attend the meeting in person and vote, your proxy appointment will automatically be terminated. . In light of the Covid-19 pandemic situation and the possibility of restrictions on travel or meetings at the time of the AGM, Shareholders are urged to appoint the Chair of the meeting as his or her proxy.

APPOINTMENT

  1. A proxy does not need to be a member of the Company but must attend the meeting to represent you. If you wish to appoint a proxy other than the chair of the meeting, insert their full name in the box. If you leave this space blank, the chair of the meeting will be appointed your proxy. In light of the Covid-19 pandemic situation and the possibility of restrictions on travel or meetings at the time of the AGM, Shareholders are urged to appoint the Chair of the meeting as his or her proxy.
  2. You may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy, additional proxy forms may be obtained by contacting the Company's registrar or you may copy this form. If you are appointing more than one proxy, please indicate in the box next to the proxy holder's name the number of shares in relation to which they are authorised to act as your proxy and indicate by ticking the relevant box that the proxy appointment is one of multiple appointments being made. Multiple proxy appointments should be returned together in the same envelope.
  3. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).

VOTING DIRECTIONS

6. To direct your proxy how to vote on the resolutions mark the appropriate box with an 'X'. To abstain from voting on a resolution, select the relevant "Vote withheld" box. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution. If no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the meeting, including a motion to adjourn.

RETURNING YOUR FORM OF PROXY

  1. To appoint a proxy using this form, the form must be:
    • Completed and signed;
    • Sent or delivered to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds, LS1 4DL; and
    • Received by Link Group no later than 11.00 a.m. on 22 September 2021.
  2. In the case of a member which is a company, this proxy form must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which this proxy form is signed (or a duly certified copy of such power or authority) must be included with the proxy form.
  3. As an alternative to completing this hard-copy proxy form, you can appoint a proxy electronically at www.signalshares.com. For an electronic proxy appointment to be valid, your appointment must be received by Link Group no later than 11.00 a.m. on 22 September 2021.
  4. CREST members who wish to appoint a proxy or proxies by using the CREST electronic appointment service may do so by using the procedures described in the CREST Manual. To be valid, the appropriate CREST message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instructions given to a previously appointed proxy, must be transmitted so as to be received by our agent ID RA 10 by 11.00 a.m. on 22 September 2021. See the notes to the notice of meeting for further information on proxy appointment through CREST.
  5. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence. For details of how to change your proxy instructions or revoke your proxy appointment, see the notes to the notice of meeting.
  6. You may not use any electronic address provided in this proxy form to communicate with the Company for any purposes other than those expressly stated.

Perivan 261615

Business Reply Plus

Licence Number

RUCA-ESGL-RSXY

TTDTDTFTDAFTTADTDFATTTFFDTDTDDATTTAD

PXSq1

Link Group

Central Square

29 Wellington Streetq

LEEDS LS1 4DL

Attachments

  • Original document
  • Permalink

Disclaimer

Fusion Antibodies plc published this content on 01 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 September 2021 06:11:06 UTC.